p53 Phosphorylation Inhibition for Haematopoietic Stem Cell Gene Therapy

Solution Overview

Problem

Current methods for genetic modification of haematopoietic stem and progenitor cells using viral vectors face challenges such as high vector doses, prolonged transduction times, and acute responses like DNA damage and apoptosis, which affect cell survival and engraftment, limiting their clinical applications.

Innovation Solution

Inhibition of p53 activation, particularly through inhibiting p53 phosphorylation by kinases like ATM and ATR, is used to improve the survival and engraftment of transduced haematopoietic stem and progenitor cells, enhancing their genetic modification process.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If high vector doses are used for genetic modification of haematopoietic stem and progenitor cells, then transduction efficiency is improved, but cell survival and engraftment are reduced due to DNA damage and apoptosis

Engineering Contradiction:

Improvetransduction efficiencyVSAvoidcell survival and engraftment

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by pre-treating haematopoietic stem and progenitor cells with a p53 inhibitor before viral transduction. This preliminary intervention prevents the activation of p53-mediated DNA damage responses that would otherwise be triggered by high vector doses, thereby maintaining both high transduction efficiency and cell survival during the subsequent transduction process

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful effect of p53 activation (which causes apoptosis and reduces engraftment) into a beneficial outcome by using p53 inhibition. The p53 pathway, which normally responds to DNA damage by inducing cell death, is deliberately blocked to allow cells to survive the stress of high-dose viral transduction while still achieving efficient genetic modification

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Productivity

If prolonged ex vivo transduction times are used to improve genetic modification, then transduction efficiency is improved, but cell survival is reduced due to acute DNA damage responses

Engineering Contradiction:

Improvetransduction efficiencyVSAvoidcell survival during culture

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by pre-treating haematopoietic stem and progenitor cells with a p53 inhibitor before viral transduction. This preliminary intervention prevents the activation of p53-mediated DNA damage responses that would otherwise be triggered by high vector doses, thereby maintaining both high transduction efficiency and cell survival during the subsequent transduction process

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses a p53 inhibitor as an intermediary substance that mediates between the viral vector and the cell's DNA damage response pathway. The inhibitor blocks the harmful signaling cascade that would normally be activated by viral DNA, allowing prolonged transduction times to be used without triggering apoptotic responses

Inventive Principle:

Principle #24Intermediary (Mediator)

3Stability of the object's composition

If viral vectors are used for genetic modification, then stable integration and long-term correction are achieved, but acute DNA damage responses and apoptosis are triggered

Engineering Contradiction:

Improvestable integration of corrective DNAVSAvoidDNA damage response and apoptosis

Core Design Contradiction:

Stability of the object's compositionVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of p53 activation (which causes apoptosis and reduces engraftment) into a beneficial outcome by using p53 inhibition. The p53 pathway, which normally responds to DNA damage by inducing cell death, is deliberately blocked to allow cells to survive the stress of high-dose viral transduction while still achieving efficient genetic modification

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent uses a p53 inhibitor as an intermediary substance that mediates between the viral vector and the cell's DNA damage response pathway. The inhibitor blocks the harmful signaling cascade that would normally be activated by viral DNA, allowing prolonged transduction times to be used without triggering apoptotic responses

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Inhibition of p53 activation leads to reduced apoptosis and improved engraftment of transduced cells, increasing their survival and functionality, thereby benefiting gene therapy treatments for various diseases.

Implementation Method 1

Inhibition of p53 activation, particularly through inhibiting p53 phosphorylation by kinases like ATM and ATR

Methodology Applied

Scientific Effectp53 phosphorylation inhibition:

Implementation Method 2

Inhibition of p53 activation, particularly through inhibiting p53 phosphorylation by kinases like ATM and ATR

Methodology Applied

Scientific Effectp53 phosphorylation inhibition:

Data Source

PatentUS20250325705A1Gene therapy

Publication Date: 2025.10.23 FOND AZIONE TELETHON

AI summary

An inhibitor of p53 activation for use in haematopoietic stem and/or progenitor cell gene therapy, preferably wherein the inhibitor is an inhibitor of p53 phosphorylation, more preferably an inhibitor of p53 Serine 15 phosphorylation.